Literature DB >> 28213792

Validation of the American Joint Commission on Cancer (AJCC) 8th Edition Staging System for Patients with Pancreatic Adenocarcinoma: A Surveillance, Epidemiology and End Results (SEER) Analysis.

Sivesh K Kamarajah1, William R Burns2, Timothy L Frankel2, Clifford S Cho2, Hari Nathan3.   

Abstract

BACKGROUND: The 8th edition of the AJCC staging system for pancreatic cancer incorporated several significant changes. This study sought to evaluate this staging system and assess its strengths and weaknesses relative to the 7th edition AJCC staging system.
METHODS: Using the Surveillance, Epidemiology and End Results (SEER) database (2004-2013), 8960 patients undergoing surgical resection for non-metastatic pancreatic adenocarcinoma were identified. Overall survival was estimated using the Kaplan-Meier method and compared using log-rank tests. Concordance indices (c-index) were calculated to evaluate the discriminatory power of both staging systems. The Cox proportional hazards model was used to determine the impact of T and N classification on overall survival.
RESULTS: The c-index for the AJCC 8th staging system [0.60; 95% confidence interval (CI), 0.59-0.61] was comparable with that for the 7th edition AJCC staging system (0.59; 95% CI, 0.58-0.60). Stratified analyses for each N classification system demonstrated a diminishing impact of T classification on overall survival with increasing nodal involvement. The corresponding c-indices were 0.58 (95% CI, 0.55-0.60) for N0, 0.53 (95% CI, 0.51-0.55) for N1, and 0.53 (95% CI, 0.50-0.56) for N2 classification.
CONCLUSION: This is the first large-scale validation of the AJCC 8th edition staging system for pancreatic cancer. The revised system provides discrimination similar to that of the 7th-edition system. However, the 8th-edition system allows for finer stratification of patients with resected tumors according to extent of nodal involvement.

Entities:  

Mesh:

Year:  2017        PMID: 28213792     DOI: 10.1245/s10434-017-5810-x

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  65 in total

Review 1.  Eighth Edition of the UICC Classification of Malignant Tumours: an overview of the changes in the pathological TNM classification criteria-What has changed and why?

Authors:  Luca Bertero; Federica Massa; Jasna Metovic; Roberto Zanetti; Isabella Castellano; Umberto Ricardi; Mauro Papotti; Paola Cassoni
Journal:  Virchows Arch       Date:  2017-12-05       Impact factor: 4.064

2.  The American Joint Committee on Cancer 8th edition staging system for the pancreatic ductal adenocarcinoma: is it better than the 7th edition?

Authors:  Dong Woo Shin; Jaihwan Kim
Journal:  Hepatobiliary Surg Nutr       Date:  2020-02       Impact factor: 7.293

3.  Association of Treatment Inequity and Ancestry With Pancreatic Ductal Adenocarcinoma Survival.

Authors:  Danielle R Heller; Norman G Nicolson; Nita Ahuja; Sajid Khan; John W Kunstman
Journal:  JAMA Surg       Date:  2020-02-19       Impact factor: 14.766

4.  High immune cell score predicts improved survival in pancreatic cancer.

Authors:  Kyösti Tahkola; Jukka-Pekka Mecklin; Erkki-Ville Wirta; Maarit Ahtiainen; Olli Helminen; Jan Böhm; Ilmo Kellokumpu
Journal:  Virchows Arch       Date:  2018-01-22       Impact factor: 4.064

Review 5.  Everolimus for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC).

Authors:  Hani M Babiker; Michael Karass; Alejandro Recio-Boiles; Sreenivasa R Chandana; Ali McBride; Daruka Mahadevan
Journal:  Expert Opin Investig Drugs       Date:  2019-06-21       Impact factor: 6.206

6.  Role of adjuvant therapy in resected stage IA subcentimeter (T1a/T1b) pancreatic cancer.

Authors:  Walid L Shaib; Amit Surya Narayan; Jeffrey M Switchenko; Sujata R Kane; Christina Wu; Mehmet Akce; Olatunji B Alese; Pretesh R Patel; Shishir K Maithel; Juan M Sarmiento; David A Kooby; Bassel F El-Rayes
Journal:  Cancer       Date:  2018-11-20       Impact factor: 6.860

7.  International Validation of the Eighth Edition of the American Joint Committee on Cancer (AJCC) TNM Staging System in Patients With Resected Pancreatic Cancer.

Authors:  Stijn van Roessel; Gyulnara G Kasumova; Joanne Verheij; Robert M Najarian; Laura Maggino; Matteo de Pastena; Giuseppe Malleo; Giovanni Marchegiani; Roberto Salvia; Sing Chau Ng; Susanna W de Geus; Sanne Lof; Francesco Giovinazzo; Jacob L van Dam; Tara S Kent; Olivier R Busch; Casper H van Eijck; Bas Groot Koerkamp; Mohammed Abu Hilal; Claudio Bassi; Jennifer F Tseng; Marc G Besselink
Journal:  JAMA Surg       Date:  2018-12-19       Impact factor: 14.766

Review 8.  Early detection of pancreatic cancer using DNA-based molecular approaches.

Authors:  Aatur D Singhi; Laura D Wood
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-06-07       Impact factor: 46.802

9.  Appropriateness of pancreatic resection in high-risk individuals for familial pancreatic ductal adenocarcinoma: a patient-level meta-analysis and proposition of the Beaujon score.

Authors:  Louis de Mestier; Marie Muller; Jérôme Cros; Marie-Pierre Vullierme; Dewi Vernerey; Frédérique Maire; Safi Dokmak; Vinciane Rebours; Alain Sauvanet; Philippe Lévy; Pascal Hammel
Journal:  United European Gastroenterol J       Date:  2019-01-12       Impact factor: 4.623

10.  Analyzing outcomes of neoadjuvant and adjuvant treatment for borderline-resectable pancreatic adenocarcinoma in the perioperative period at an academic institution.

Authors:  Alejandro Recio-Boiles; Jessica Vondrak; Summana Veeravelli; James J Mancuso; Kathylynn Saboda; Denise J Roe; Irbaz Bin Riaz; Aaron J Scott; Emad Elquza; Ali McBride; Hani M Babiker
Journal:  Ann Pancreat Cancer       Date:  2020-03-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.